Pharmaceutical companies are making commercial decisions in increasingly complex therapy markets. Shifting patient needs, uncertain launch trajectories, evolving competition, and fragmented healthcare data can make long-term forecasting difficult. Generative AI and advanced analytics are opening new possibilities, but their value depends on how well organizations integrate them into strategic planning.
The AI, Forecasting, Insights and Analytics for Smarter Decisions in Pharma 2026, organized by Marcus Evans, takes place on November 16–17 in London, UK. The conference will bring together pharmaceutical forecasting, market access, analytics, and commercial strategy leaders to examine how AI and real-world evidence can improve decision-making.
Moving from Forecasting to Strategic Foresight
A central theme is the use of Agentic AI and Real-World Evidence (RWE) to prepare for multiple market scenarios. Sessions will explore how pharmaceutical companies can move beyond conventional forecasting models to anticipate changes in therapy markets, strengthen assumptions, and improve long-term planning.
Rare disease forecasting is another important focus. Integrating patient-centric insights with broader healthcare data can help organizations navigate markets where traditional forecasting approaches may offer limited visibility. The agenda also examines lifecycle forecasting and how commercial teams can build greater agility in volatile and high-growth therapy markets.
Data governance and analytical integrity form the foundation of these discussions. As companies introduce AI into forecasting and commercial workflows, they must maintain confidence in the underlying data, establish shared governance models, and ensure that AI-generated insights support sound business decisions.
Through case studies, expert-led panels, roundtables, and interactive workshops, the conference will connect AI adoption with the practical demands of pharmaceutical strategy.
Also Read: Agentic AI Conference 2026: Making Autonomous AI Secure, Governable and Useful
Pharma Forecasting and Analytics Leaders on the Lineup
The confirmed speakers include Alireza Moayyeri, Digital Excellence Lead, RWE and Market Access at UCB, and Gerardo Martinez, Senior Director, Global Market Access – Pipeline (Immunology & Rare Diseases) at CSL Behring.
Also featured are Danilo Pelosi, Senior Director, Rare Diseases Cluster International at Chiesi Group, and Paul Boutry, Head of Strategic Planning & Analytics at BioMarin. Their experience across market access, rare diseases, and strategic planning reflects the commercial and analytical questions at the centre of the conference.
Other speakers include Christopher Meyer of Ferring Pharmaceuticals, Stefano Garini of Recordati, Peter Elsig Raun of Lundbeck, and Stephen O’Shea of GSK.
Explore the full speaker lineup and conference details here.
For pharmaceutical executives and forecasting professionals, the event offers an opportunity to examine how AI, real-world evidence, and stronger analytics capabilities can support more confident commercial decisions.
To know more about the conference, agenda, and registration, visit the official Marcus Evans event website.


